Levetiracetam Injection, Solution, Concentrate
Product Images NDC 72205-120

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72205-120). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levet-inj-10s-crtn-label (Levet Inj 10s Crtn Label)

Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) injection solution concentrate for intravenous use. The label indicates a package of 10 single-dose vials, each vial containing 5 mL. Distributed by Novadoz Pharmaceuticals LLC and manufactured by MSN Laboratories Private Limited in India. The label includes storage instructions and notes that the product must be diluted prior to administration.*

FDA Label Image

Levet-inj-25s-crtn-label (Levet Inj 25s Crtn Label)

Packaging label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous solution concentrate. The label indicates single-dose vials, 25 vials per package. Distributed by Novadoz Pharmaceuticals LLC and manufactured by MSN Laboratories Private Limited in India. Storage instructions and dilution requirements prior to administration are also noted.*

FDA Label Image

Levet-inj-figure-1 (Levet Inj Figure 1)

A bar graph showing the percentage of patients responding to different treatments: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The x-axis presents the treatment groups and their sample sizes, while the y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Levet-inj-figure-2 (Levet Inj Figure 2)

A bar graph showing the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The x-axis lists treatment groups with patient counts, and the y-axis indicates the percentage of patients from 0% to 45%.*

FDA Label Image

Levet-inj-figure-3 (Levet Inj Figure 3)

A bar chart comparing the percentage of patients between a placebo group (14.4%) and a Levetiracetam 3000 mg/day group (39.4%). The vertical axis shows the percentage of patients, and the horizontal axis lists the two groups with their respective sample sizes (N=104 for placebo, N=180 for Levetiracetam). An asterisk marks the Levetiracetam bar.*

FDA Label Image

Levet-inj-figure-4 (Levet Inj Figure 4)

A vertical bar graph displaying the percentage of patients in two groups: Placebo with 19.6% and Levetiracetam with 44.6%. The y-axis is labeled '% of Patients' and ranges from 0% to 45%. The x-axis labels indicate the group names and sample sizes: Placebo (N=97) and Levetiracetam (N=101). The Levetiracetam bar contains an asterisk symbol above it.*

FDA Label Image

Levet-inj-figure-5 (Levet Inj Figure 5)

A bar graph comparing the percentage of patients responding to treatment between placebo and Levetiracetam groups. The vertical axis shows the percentage of patients from 0% to 45%. The placebo group (N=51) has a response rate of 19.6%, while the Levetiracetam group (N=58) shows a higher response rate of 43.1%, marked with an asterisk indicating statistical significance.*

FDA Label Image

Levet-inj-figure-6 (Levet Inj Figure 6)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The y-axis represents the percentage of patients from 0% to 100%. The placebo group (N=84) shows 45.2%, while the Levetiracetam group (N=79) shows 72.2%, marked with an asterisk indicating significance.*

FDA Label Image

Levet-inj-structure (Levet Inj Structure)

Chemical structure of Levetiracetam, showing its molecular arrangement with key functional groups including an amide and a pyrrolidone ring.*

FDA Label Image

Levet-inj-vial-labl (Levet Inj Vial Labl)

Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous injection solution concentrate in a 5 mL single-dose vial. The label states it must be diluted prior to administration. Manufactured by MSN Laboratories Private Limited, India, and distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.